ERBB2 and non-small cell lung carcinoma: The combination of trastuzumab and pertuzumab alone or in combination with docetaxel also did not report encouraging results, with ORRs of 8–21% in dual blockade alone and an ORR of 29% in dual blockade plus docetaxel in pretreated NSCLC patients with HER2 AMP or MUT [59,60,61].